Superobese Patients
- Conditions
- Obesity
- Interventions
- Procedure: Bariatric surgery
- Registration Number
- NCT05446246
- Lead Sponsor
- University of Cagliari
- Brief Summary
Super obesity (SO) is defined as a Body Mass Index (BMI) \> 50 kg/m2, and represents the extreme severity of the disease, resulting in an increase in morbidity, mortality, and in poorer quality of life compared with morbid obesity (BMI \> 35 and \<50 kg/m2).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Morbid and superobese patients
Exclusion Criteria
- Follow up not completed
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Superobese patients Bariatric surgery Patients with preoperative BMI \> 50 Morbidobese patients Bariatric surgery Patients with preoperative BMI \> 35 and \<50
- Primary Outcome Measures
Name Time Method Surgical success 24 months BMI \<35
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are linked to post-bariatric surgery weight regain in superobese patients (BMI >50 kg/m²)?
How does bariatric surgery compare to standard-of-care pharmacotherapy (e.g., semaglutide) in long-term weight loss for superobese patients (BMI >50 kg/m²)?
Which genetic or metabolic biomarkers predict failure in superobese patients undergoing bariatric surgery (NCT05446246)?
What are the adverse event profiles in superobese patients post-bariatric surgery compared to morbidly obese counterparts?
Are GLP-1 receptor agonists effective when combined with bariatric surgery for superobese patients (BMI >50 kg/m²)?
Trial Locations
- Locations (1)
AOU Cagliari
🇮🇹Cagliari, CA, Italy